Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corporation reports recurring developments as a medical technology company focused on reconstructive surgery, rehabilitation, pain management, physical therapy and musculoskeletal care. Company news centers on financial results, guidance, organic sales trends and segment performance in Reconstructive and Prevention & Recovery, including updates tied to new product introductions and end-market conditions.
Enovis announcements also include conference participation and investor presentation activity, with business commentary on clinically differentiated solutions intended to enhance patient outcomes, restore motion and support surgeons, clinicians and other healthcare professionals.
Enovis Corporation (NYSE: ENOV) reported third-quarter 2022 sales of $384 million, a 7% increase year-over-year, driven by double-digit growth in its Reconstructive segment. However, the company faced a net loss of $(66) million or $(1.22) per diluted share. Adjusted earnings per share improved by 34% to $0.59, with adjusted EBITDA at $57 million, representing 14.9% of sales. Enovis launched innovative products, including the EMPOWR 3D Knee™ and connected bracing solutions. The company anticipates total sales growth of approximately 10% for 2022.
Enovis Corporation (NYSE: ENOV) has announced participation in two investor conferences this November. CFO Chris Hix and incoming CFO Ben Berry will speak at the Credit Suisse 31st Annual Healthcare Conference on November 8 in Rancho Palos Verdes, CA. Later, on November 29, CEO Matt Trerotola and Ben Berry will participate in the Evercore ISI 5th Annual HEALTHCONx virtual conference. Enovis specializes in medical technology and is committed to improving patient outcomes through innovative solutions.
Enovis Corporation (NYSE: ENOV) will host an investor conference call and live webcast on November 2, 2022, at 8:00 AM ET to discuss its Q3 2022 financial results. An earnings press release will precede the call. Investors can access the live webcast through the Enovis website, and for participation, U.S. callers can dial (800) 715-9871, while international callers should use (646) 307-1963 with conference ID 1914045. A replay will also be available later on the website. Enovis focuses on innovative medical solutions for improved patient outcomes.
Enovis Corporation (NYSE: ENOV) is set to showcase its expanding foot and ankle portfolio at the AOFAS annual meeting in Quebec City from September 14-17, 2022. Highlighting recent FDA-cleared products like DynaClip Delta™ and DynaClip Quattro™, the company aims to enhance patient outcomes through innovative solutions. Enovis will also present its Future of STAR® Ankle and offer hands-on workshops. The company remains committed to driving technological advancements in the orthopedic sector.
Enovis Corporation (NYSE: ENOV) has announced participation in two key investor conferences in September 2022. The Wells Fargo Healthcare Conference will be held on September 7 in Boston, featuring CEO Matt Trerotola and CFO Ben Berry. Following this, the Baird Global Healthcare Conference is on September 14 in New York, with Trerotola and outgoing CFO Chris Hix attending. Enovis focuses on medical technology innovations that improve patient outcomes and efficiency in orthopedics.
Enovis Corporation (NYSE: ENOV) reported second quarter 2022 sales of $395 million, marking an 11% increase. Operating income stood at $6 million, with adjusted EBITDA rising 11% to $56 million. The net income was $121 million, equating to $2.21 per diluted share, while adjusted earnings per share surged 44% to $0.59. The company updated its full-year adjusted EBITDA outlook to $235-255 million, adjusting its EPS guidance to $2.15-$2.35 due to currency pressures and a tax benefit. Enovis recently acquired Insight Medical Systems and 360 Med Care, expanding its market reach and innovation.
Enovis (NYSE: ENOV) has launched its ARVIS (Augmented Reality Visualization and Information System), a groundbreaking AR technology aimed at orthopedic surgery. Over 200 successful cases in the U.S. demonstrate its application in enhancing the precision of hip and knee implant placements. Unlike traditional robotic systems, ARVIS is hands-free and reduces the need for extra staff, making it accessible to various surgical centers. This innovation is not only effective but also environmentally sustainable by eliminating single-use plastics.
Enovis Corporation (NYSE: ENOV) announced an investor conference call for its second quarter 2022 financial results, scheduled for August 4, 2022, at 8:00 AM ET. An earnings press release will be issued that morning, and a presentation will be available on the company's website. Investors can access the live webcast through the Enovis site or by calling (800) 715-9871 (U.S.) or (646) 307-1963 (International) with conference ID 1950250. A replay of the call will also be made available later the same day.
Enovis Corporation (NYSE: ENOV) has acquired Insight Medical Systems, enhancing its reconstructive portfolio with the FDA-cleared ARVIS® augmented reality surgical guidance technology. This acquisition aims to improve patient outcomes in hip and knee replacements. The ARVIS® system, already in use for over 200 cases in the U.S., offers real-time, hands-free guidance and is expected to be commercially available in Q3 2022. Enovis anticipates further growth and innovation by integrating this technology into its surgical business.
Enovis Corporation (NYSE: ENOV) announced the appointment of Ben Berry as the new Chief Financial Officer, effective January 1, 2023. Berry succeeds Chris Hix, who will transition to an advisory role until his retirement later in 2023. CEO Matt Trerotola praised Berry for his financial leadership and contributions to the company's growth strategy and improved operational performance since joining in 2020. Hix has played a pivotal role in transforming Enovis into a specialized medical technology leader since 2016.